Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$0.84 +1.3%	$1.07	$0.79 ▼ $4.00	$26.90M	0.22	31,207 shs	81,487 shs
BMRA Biomerica	$3.15 -0.2%	$3.28	$2.08 ▼ $10.16	$8.01M	0.26	628,577 shs	16,091 shs
MDCX Medicus Pharma	$2.02 -0.5%	$2.64	$1.80 ▼ $8.94	$36.00M	N/A	230,959 shs	327,736 shs
SNYR Synergy CHC	$2.17 +3.8%	$3.24	$1.30 ▼ $10.00	$20.49M	N/A	454,104 shs	142,990 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	-1.63%	-10.94%	-25.46%	-34.67%	-77.44%
BMRA Biomerica	-4.26%	-1.87%	-13.82%	-0.32%	-19.86%
MDCX Medicus Pharma	-0.49%	-0.49%	-16.80%	-44.08%	+202,999,900.00%
SNYR Synergy CHC	-9.13%	-26.92%	-43.82%	+15.47%	+1,990.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	3.0575 of 5 stars	3.5	3.0	3.3	3.3	0.0
BMRA Biomerica	1.1095 of 5 stars	0.0	5.0	3.3	0.8	0.0
MDCX Medicus Pharma	1.6902 of 5 stars	3.8	0.0	1.8	0.8	0.0
SNYR Synergy CHC	4.3679 of 5 stars	3.8	0.0	3.0	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	3.00	Buy	$5.00	498.09% Upside
BMRA Biomerica	0.00	N/A	N/A	N/A
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	1,063.37% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	360.83% Upside

Current Analyst Ratings Breakdown

Latest BMRA, SNYR, MDCX, and AKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/18/2025	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.80 per share	N/A
BMRA Biomerica	$5.68M	1.41	N/A	N/A	$3.13 per share	1.00
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.18 per share	N/A
SNYR Synergy CHC	$33.70M	0.61	$0.25 per share	8.65	($1.31) per share	-1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-78.03%	-31.62%	9/25/2025 (Estimated)
BMRA Biomerica	-$5.98M	-$2.32	N/A	∞	N/A	-85.42%	-85.90%	-61.06%	N/A
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
SNYR Synergy CHC	$2.12M	$0.38	5.71	3.68	N/A	10.02%	-18.56%	20.28%	N/A

Latest BMRA, SNYR, MDCX, and AKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2025	Q2 2025	AKTX Akari Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SNYR Synergy CHC	$0.08	$0.17	+$0.09	$0.17	$10.80 million	$6.74 million
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
BMRA Biomerica	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.19	0.19
BMRA Biomerica	N/A	3.76	2.76
MDCX Medicus Pharma	N/A	1.29	1.29
SNYR Synergy CHC	N/A	2.74	2.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
BMRA Biomerica	22.28%
MDCX Medicus Pharma	N/A
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.10%
BMRA Biomerica	15.00%
MDCX Medicus Pharma	11.20%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
BMRA Biomerica	60	2.55 million	2.16 million	Optionable
MDCX Medicus Pharma	N/A	17.82 million	15.82 million	N/A
SNYR Synergy CHC	40	9.44 million	4.10 million	N/A

BMRA, SNYR, MDCX, and AKTX Headlines

Recent News About These Companies

Synergy CHC Completes $4.375M Public Offering

August 27 at 5:30 PM | tipranks.com

Synergy CHC Corp. Announces the Closing of its $4.375 Million Public Offering

August 27 at 4:15 PM | globenewswire.com

Synergy CHC (SNYR) & The Competition Financial Comparison

August 26 at 4:35 AM | americanbankingnews.com

Synergy CHC 1.75M share Secondary priced at $2.50

August 26 at 3:19 AM | msn.com

Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering | SNYR Stock News

August 25 at 10:10 PM | gurufocus.com

Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering of Common Stock

August 25 at 9:51 PM | quiverquant.comQ

Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering

August 25 at 9:30 PM | globenewswire.com

Synergy CHC's (NASDAQ:SNYR) Earnings Quality Is Low

August 22, 2025 | finance.yahoo.com

Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th

August 21, 2025 | markets.businessinsider.com

New to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...

August 20, 2025 | palmbeachpost.comP

Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy

August 18, 2025 | taiwannews.com.twT

New to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...

August 18, 2025 | finanznachrichten.de

Synergy CHC announces major distribution with for FOCUSfactor Focus + Energy

August 18, 2025 | msn.com

Synergy CHC Expands FOCUSfactor Distribution with EG America

August 18, 2025 | tipranks.com

Analysts Set Expectations for Synergy CHC FY2025 Earnings

August 18, 2025 | americanbankingnews.com

Synergy CHC files to sell 1.28M shares of common stock

August 15, 2025 | msn.com

Synergy Chc EPS Jumps 86 Percent in Q2

August 15, 2025 | theglobeandmail.com

Synergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | finanznachrichten.de

Synergy CHC reports Q2 EPS 17c vs 9c last year

August 14, 2025 | msn.com

Synergy CHC Corp. Reports Strong Second Quarter 2025 Financial Results with Significant Year-over-Year Growth

August 14, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, SNYR, MDCX, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$0.84 +0.01 (+1.33%)

As of 03:38 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Biomerica NASDAQ:BMRA

$3.14 -0.01 (-0.16%)

As of 03:28 PM Eastern

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Medicus Pharma NASDAQ:MDCX

$2.02 -0.01 (-0.49%)

As of 03:16 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Synergy CHC NASDAQ:SNYR

$2.17 +0.08 (+3.83%)

As of 03:20 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time